Date: 03/09/2022

Rachel Lefferdink # 1, Stephanie M Rangel # 1, Margot Chima 2, Erin Ibler 1, Ana B Pavel 2 3, HeeJin Kim 2, Benedict Wu 1, Hajar Abu-Zayed 1, Jianni Wu 2, Kathryn Jackson 4, Giselle Singer 2, Keith A Choate 5, Emma Guttman-Yassky # 6, Amy S Paller # 7

PubMed

PMID: 35218370 DOI: 10.1007/s00403-022-02325-3

Abstract

Importance: Treatment of congenital ichthyoses primarily focuses on reversing skin scaling and is not pathogenesis based. Recent studies showed Th17 immune skewing, as in psoriasis, across the spectrum of ichthyosis, suggesting that targeting this pathway might broadly reduce disease severity.

Objective: To determine whether secukinumab, an IL-17A inhibitor, can improve ichthyosis across several congenital ichthyosis subtypes.

Design: Exploratory 16-week double-blind, randomized, placebo-controlled trial comparing secukinumab 300 mg every 4wks to placebo (1:1 randomization) in adults with the four major congenital ichthyosis subtypes (NCT03041038), followed by a 16-week open-label phase to evaluate response of the placebo-first group and a 20-week extension for safety. Significant differences in secukinumab- vs. placebo-treated subjects at Wk16 in the Ichthyosis Area Severity Index (IASI) score and lack of increased mucocutaneous bacterial and/or fungal infections were the co-primary efficacy and safety endpoints, respectively.

Setting: Two tertiary referral centers: Northwestern University Feinberg School of Medicine, Chicago, and Mount Sinai Icahn School of Medicine, New York.

Participants: Twenty subjects ≥ 18 yo with genotype-confirmed epidermolytic ichthyosis, Netherton syndrome, lamellar ichthyosis, or congenital ichthyosiform erythroderma with at least moderate erythroderma.

Results: IL-17A inhibition did not significantly reduce severity or increase mucocutaneous infections among the 18 who completed the 16-week double-blind phase. Five patients with 29-50% clinical improvement at Wk32 requested drug continuation. Th17-related biomarkers were not significantly reduced vs. baseline or placebo-treated levels.

Limitations: Small sample size; heterogeneous ichthyosis subsets.

Conclusion: IL-17 inhibition with secukinumab is safe, but not efficacious across the spectrum of adult ichthyoses. CLINICALTRIALS.

Gov registration number: NCT03041038; first posted on 02/02/2017.

Keywords: Biologic; IL-17; Ichthyosis; Monoclonal antibody; Secukinumab.

© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

References

AS, Renert-Yuval Y, Suprun M, Esaki H, Oliva M, Huynh TN, et al. (2017) An IL-17–dominant immune profile is shared across the major orphan forms of ichthyosis. J Allergy Clin Immunol 139:152-165. https://doi.org/10.1016/j.jaci.2016.07.019

Malik K, He H, Huynh TN, Tran G, Mueller K, Doytcheva K et al (2019) Ichthyosis molecular fingerprinting shows profound TH17 skewing and a unique barrier genomic signature. J Allergy Clin Immunol 143:604–618. https://doi.org/10.1016/j.jaci.2018.03.021 - DOI - PubMed

Czarnowicki T, He H, Leonard A, Malik K, Magidi S, Rangel S et al (2018) The major orphan forms of ichthyosis are characterized by systemic T-cell activation and Th-17/Tc-17/Th-22/Tc-22 polarization in blood. J Invest Dermatol 138:2157–2167. https://doi.org/10.1016/j.jid.2018.03.1523 - DOI - PubMed

Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K et al (2015) Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol 73:400–409. https://doi.org/10.1016/j.jaad.2015.05.013 - DOI - PubMed

Marukian NV, Deng Y, Gan G, Ren I, Thermidor W, Craiglow BG et al (2017) Establishing and validating an ichthyosis severity index. J Invest Dermatol 137:1834–1841. https://doi.org/10.1016/j.jid.2017.04.037 - DOI - PubMed

Bodemer C, Bourrat E, Mazereeuw-Hautier J, Boralevi F, Barbarot S, Bessis D, Blanchet-Bardon C et al (2011) Short- and medium-term efficacy of specific hydrotherapy in inherited ichthyosis. Br J Dermatol 165:1087–1094. https://doi.org/10.1111/j.1365-2133.2011.10510 - DOI - PubMed

Erickson TR, Murphrey MB, Abu-Zayed H, Wu B, Ibler E, Rangel SM et al (2020) Transepidermal water loss in the orphan forms of ichthyosis. Pediatr Dermatol 37:771–773. https://doi.org/10.1111/pde.14221 - DOI - PubMed

Elman S, Hynan LS, Gabriel V, Mayo MJ (2009) The 5-D itch scale: a new measure of pruritus. Br J Dermatol 162:587–593. https://doi.org/10.1111/j.1365-2133.2009.09586 - DOI - PubMed - PMC

Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY (2008) The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results. Br J Dermatol 159:997–1035. https://doi.org/10.1111/j.1365-2133.2008.08832 - DOI - PubMed

Dreyfus I, Taïeb C, Barbarot S, Maza A, Galera I, Bourrat E, et al. et al (2013) iQoL-32: a new ichthyosis-specific measure of quality of life. J Am Acad Dermatol 69:82–87. https://doi.org/10.1016/j.jaad.2013.01.022 - DOI - PubMed

Krueger JG, Wharton KA Jr, Schlitt T, Suprun M, Torene RI, Jiang X et al (2019) IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis. J Allergy Clin Immunol 144:750–763. https://doi.org/10.1016/j.jaci.2019.04.029 - DOI - PubMed

Hernández-Martín A, Kennedy-Batalla R, Cañedo E, González-Sarmiento R, Kennedy-Batalla Rebeca, Martínez-Bonet Marta, et al. (2019) Imbalance in T-helper 17 cells and targeted therapy in an infant with SAM-like syndrome. N Engl J Med 381:2176–2178. https://doi.org/10.1056/NEJMc1908531

Paller AS. (2020) Pathogenesis-based therapy with repurposed biologics for monogenic inflammatory skin disorders. JAMA Dermatol 156:839–41. https://doi.org/10.1001/jamadermatol.2020.1018

Luchsinger I, Knöpfel N, Theiler M, Bonnet des Claustres M, Barbieux C, Schwieger-Briel A, et al. (2020) Secukinumab therapy for Netherton syndrome. JAMA Dermatol156:907–11. https://doi.org/10.1001/jamadermatol.2020.1019

Blanchard SK, Prose NS (2020) Successful use of secukinumab in Netherton syndrome. JAAD Case Rep 6:577–578. https://doi.org/10.1016/j.jdcr.2020.04.025 - DOI - PubMed - PMC

Paller AS, Czarnowicki T, Renert-Yuval Y, Holland K, Huynh T, Sadlier M, et al. (2018) The spectrum of manifestations in desmoplakin gene (DSP) spectrin repeat 6 domain mutations: Immunophenotyping and response to ustekinumab. J Am Acad Dermatol 78:498–505.e2. https://doi.org/10.1016/j.jaad.2017.10.026

Sun Q, Wine Lee L, Hall EK, Choate KA, Elder RW. (2021) Hair and skin predict cardiomyopathies: Carvajal and erythrokeratodermia cardiomyopathy syndromes. Pediatr Dermatol 38:31–38. https://doi.org/10.1111/pde.14478

Frommherz LH, Schempp CM, Has C. (2021) Secukinumab for the treatment of SAM syndrome associated with desmoglein-1 deficiency. Br J Dermatol 184:770–772. https://doi.org/10.1111/bjd.19684

Steinhoff, M, Al-Marri, F, Al Chalabi, R, Gieler, U, Buddenkotte, J. (2021) Recalcitrant erythrodermic ichthyosis with atopic dermatitis successfully treated with dupilumab in combination with guselkumab. Skin Health Dis.e87. https://doi.org/10.1002/ski2.87

Associated data

ClinicalTrials.gov/NCT03041038